Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print      Mail a friend

Thursday 06 December, 2018

BioPharma Credit PLC

Appointment of Director

RNS Number : 6067J
BioPharma Credit PLC
06 December 2018
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

Appointment of New Director

 

The Company is pleased to announce the appointment of Stephanie Léouzon as a non-executive Director of the Company, with effect from 5 December 2018.

 

Stephanie Léouzon is a Partner and Head of Torreya Europe. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion. Mrs Léouzon joined Torreya in 2011. Previously, she was a Managing Director and Senior Advisor at Credit Suisse in London. She has also worked at Salomon Brothers, as a Director of Healthcare Investment Banking, and as a Vice President in the Investment Banking divisions of JP Morgan and Lehman Brothers in New York. She was previously a non-executive director of Endotis Pharma SA and Immunovaccine Inc.

 

Mrs Léouzon holds no other publicly quoted directorships. Publicly quoted directorships held by her within the last five years are as follows:

 

Company 

 

Position

Date of resignation

Immunovaccine Inc.

 

Non-executive Director and member of Audit Committee and Chair of Finance Committee

26 September 2014

                                        

 

Mrs Léouzon is not currently, and has not been in the last five years, a director of any other publicly quoted company.

 

Endotis Pharma SA voluntarily filed for liquidation in accordance with French law in September 2012 following the failure of its lead drug in clinical development. The liquidation process was handled by an appointed liquidator and was completed on 28 February 2018.

 

There are no other details required to be disclosed under LR 9.6.13R (2) to (6) of the Financial Conduct Authority Listing Rules.

 

 

6 December 2018

 

 

 

 

LEI: 213800AV55PYXAS7SY24


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOALIFFFFTLRIIT

a d v e r t i s e m e n t